Equity Overview
Price & Market Data
Price: $1.07
Daily Change: -$0.01 / 0.93%
Range: $1.03 - $1.08
Market Cap: $88,391,632
Volume: 64,282
Performance Metrics
1 Week: 5.94%
1 Month: 0.94%
3 Months: -21.32%
6 Months: -43.98%
1 Year: -39.20%
YTD: -16.41%
Company Details
Employees: 22
Sector: Health technology
Industry: Biotechnology
Country: Canada
Details
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.